^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Nasopharyngeal Carcinoma
    Regimen: (cisplatin + gemcitabine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    12/21/2020
    Excerpt:
    Nasopharyngeal carcinoma: Recommendations...ICT with cisplatin and gemcitabine followed by CRT for locally advanced NPC is associated with a benefit in RFS, OS and distant RFS...
    DOI:
    10.1016/j.annonc.2020.12.007
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Nasopharyngeal cancer: Induction/Sequential Systemic Therapy…Preferred Regimens…Gemcitabine/cisplatin